Skip to main content

Table 2 Biologics used in the treatment of IMIDs

From: Cancer risk in immune-mediated inflammatory diseases (IMID)

Biologic

Type of molecule

IMIDs for which it is licensed

Infliximab (Remicade®)

Chimeric monoclonal antibody against TNF

RA, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn’s disease, plaque psoriasis

Adalimumab (Humira®)

Human monoclonal antibody against TNF

RA, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, polyarticular juvenile idiopathic arthritis

Golimumab (Simponi®)

Human monoclonal antibody against TNF

RA, psoriatic arthritis, ankylosing spondylitis

Certolizumab pegol (Cimzia®)

Pegylated humanized Fab’ monoclonal antibody fragment against TNF

RA, Crohn’s disease

Etanercept (Enbrel®)

Fusion protein of two TNF receptor 2 extracellular domains and the Fc portion of human IgG

RA, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis

Tocilizumab (Actemra® or RoActemra®)

Humanized monoclonal antibody against the interleukin-6 receptor

Juvenile idiopathic arthritis, RA

Rituximab (Rituxan® or MabThera®)

Chimeric anti-CD20 monoclonal antibody

RA, granulomatosis with polyangiitis (Wegener)

Abatacept (Orencia®)

Fusion of extracellular domain of human CTLA-4 and the Fc domain of IgG

RA

Alefacept (Amevive®)

Fusion of CD2-binding region of LFA-3 and the CH2 and CH3 domains of IgG1

Psoriasis

Anakinra (Kineret®)

Recombinant, non-glycosylated human IL-1 receptor antagonist

RA